Critical Care Market to 2017 - Shift of Focus Towards PCC, Factor Concentrates and Antithrombins Due to Better Safety and Efficacy Profiles
NEW YORK, Dec. 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
http://www.reportlinker.com/p0747901/Critical-Care-Market-to-2017---Shift-of-Focus-towards-PCC-Factor-Concentrates-and-Antithrombins-due-to-Better-Safety-and-Efficacy-Profiles.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy
Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles
Summary
GBI Research's report, "Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles" provides in-depth analysis of drivers and barriers that impact the global critical care market. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. This includes treatment usage patterns, average annual cost of therapy and market size forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides information on the R&D product pipeline and explores the competitive landscape, including major players in the critical care market. Finally, the report includes analysis on mergers and acquisitions (M&As) in the critical care market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
Scope
- Data and analysis on the critical care market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the critical care market that includes markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2002 to 2010, with forecasts to 2017
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume and treatment usage patterns such as disease population, diagnosis population and prescription population
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global critical care market, including top companies benchmarking. The key companies studied in this report are CSL, Octapharma, Baxter, Grifols and LFB
- Key M&A activities that took place in 2010 and 2011 in the critical care market
Reasons to buy
- Align your product portfolio to the markets with high growth potential
- Build effective strategies to launch their pipeline products by identifying potential geographies
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
- Develop key strategic initiatives by studying the key strategies of top competitors
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious
Table of Contents
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 8
2 Critical Care Market to 2017 – Introduction 9
2.1 GBI Research Report Guidance 9
3 Critical Care Market to 2017 – Global Overview 10
4 Critical Care Market to 2017 – Geographical Landscape 12
4.1 Introduction 12
4.2 The US 13
4.2.1 Revenue 13
4.3 Top Five Countries of Europe 14
4.3.1 Revenue 14
4.4 Japan 16
4.4.1 Revenue 16
5 Critical Care Market to 2017 – Therapeutic Landscape 17
5.1 Factor XIII Concentrate 17
5.1.1 Introduction 17
5.1.2 Revenue 18
5.1.3 Geographical Segmentation 21
5.1.4 Cost of Treatment 22
5.1.5 Treatment Usage Pattern 24
5.2 Drivers and Restraints 25
5.2.1 Drivers 26
5.2.2 Restraint 26
5.3 Marketed Products 27
5.3.1 Fibrogammin P / Corifact 27
5.4 Antithrombin (AT) Market 27
5.4.1 Introduction 27
5.4.2 Revenue 29
5.4.3 Geographical Segmentation 31
5.4.4 Cost of Treatment 32
5.4.5 Treatment Usage Pattern 33
5.5 Drivers and Restraints 35
5.5.1 Drivers 36
5.5.2 Restraints 36
5.6 Marketed Products 37
5.6.1 Thrombate III (Antithrombin III human) 37
5.6.2 Anbinex (Grifols SA) 37
5.6.3 Kybernin (CSL Behring GmbH) 38
5.6.4 Aclotine (Laboratory of French Split and Biotechnology) 38
5.6.5 ANTITHROMBIN III (Baxter) 38
5.6.6 Neuart (Mitsubishi Tanabe Pharma Corporation) 39
5.6.7 Atryn 39
5.7 Fibrinogen Concentrate Market 40
5.7.1 Introduction 40
5.7.2 Revenue 41
5.7.3 Geographical Segmentation 42
5.7.4 Cost of Treatment 45
5.7.5 Treatment Usage Pattern 46
5.8 Drivers and Restraints 48
5.8.1 Drivers 48
5.8.2 Barriers 48
5.9 Marketed Products 49
5.9.1 Haemocomplettan/Riastap 49
5.10 Albumin 50
5.10.1 Introduction 50
5.10.2 Revenue 51
5.10.3 Geographical Segmentation 53
5.10.4 Cost of Treatment 54
5.10.5 Treatment Usage Pattern 56
5.11 Drivers and Restraints 57
5.11.1 Drivers 57
5.11.2 Restraints 57
5.12 Marketed Products 58
5.12.1 Albuminar (CSL Behring) 58
5.12.2 Human Albumin Biotest, solution for infusion (Biotest) 58
5.12.3 Buminate 25% (Baxter) 59
5.12.4 Human Albumin Grifols 25% (Grifols SA) 59
5.13 Prothrombin Complex Concentrate Market (PCC) 59
5.13.1 Introduction 59
5.13.2 Revenue 61
5.13.3 Revenue Breakup 63
5.13.4 Geographical Segmentation 64
5.13.5 Cost of Treatment 65
5.13.6 Treatment Usage Pattern 66
5.14 Drivers and Restraints 67
5.14.1 Drivers 67
5.14.2 Barriers 68
5.15 Marketed Products 68
5.15.1 Beriplex P/N 68
5.15.2 Feiba 69
6 Critical Care Market to 2017 - Product Pipeline 70
6.1 Introduction 70
6.1.1 rFXIII (Novo Nordisk A/S) 72
7 Critical Care Market to 2017 – Competitive Landscape 73
7.1 CSL Limited 73
7.1.1 Company Overview 73
7.1.2 SWOT Analysis 74
7.2 Octapharma AG 74
7.2.1 Company Overview 74
7.2.2 SWOT Analysis 75
7.3 Baxter International Inc. 76
7.3.1 SWOT Analysis 76
7.4 Grifols SA (Grifols) 77
7.4.1 Company Overview 77
7.4.2 SWOT Analysis 78
7.5 LFB S.A. (LFB) 79
7.5.1 Company Overview 79
7.5.2 SWOT Analysis 79
8 Critical Care Market to 2017– Mergers & Acquisitions Landscape 80
8.1 LFB Biotechnologies Completes Acquisition of GTC Biotherapeutics 80
8.2 Grifols Completes Acquisition of Talecris Biotherapeutics 80
9 Critical Care Market to 2017 – Appendix 81
9.1 Market Definitions 81
9.2 Abbreviations 81
9.3 Research Methodology 82
9.3.1 Coverage 82
9.3.2 Secondary Research 82
9.3.3 Primary Research 83
9.4 Therapeutic Landscape 83
9.4.1 Epidemiology-based Forecasting 84
9.5 Geographical Landscape 86
9.6 Pipeline Analysis 86
9.7 Competitive Landscape 86
9.7.1 Expert Panel Validation 86
9.8 Contact Us 86
9.9 Disclaimer 86
9.10 Sources 87
List of Tables
1.1 List of Tables
Table 1: Critical Care Market, Global Revenue ($m), 2002-2010 11
Table 2: Critical Care Market, Global Revenue ($m), 2010-2017 11
Table 3: Critical Care Market, The US, Revenue ($m), 2002-2010 14
Table 4: Critical Care Market, The US, Revenue, ($m), 2010-2017 14
Table 5: Critical Care Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 15
Table 6: Critical Care Market, Top Five Countries of Europe, Revenue ($m), 2010-2017 15
Table 7: Critical Care Market, Japan, Revenue ($m), 2002-2010 16
Table 8: Critical Care Market, Japan, Revenue ($m), 2010-2017 16
Table 9: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($'000), 2002-2010 18
Table 10: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($'000), 2010-2017 18
Table 11: Critical Care Market, Global, Factor XIII Concentrate, Revenue Segmentation ($'000), 2002-2010 21
Table 12: Critical Care Market, Global, Factor XIII Concentrate, Revenue Segmentation ($'000), 2010-2017 22
Table 13: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2002-2010 23
Table 14: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2010-2017 23
Table 15: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2002-2010 24
Table 16: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2010-2017 24
Table 17: Critical Care Market, Global, Antithrombin, Revenue ($'000), 2002-2010 29
Table 18: Critical Care Market, Global, Antithrombin, Revenue ($'000), 2010-2017 30
Table 19: Critical Care Market, Global, Antithrombin Revenue Segmentation ($'000), 2002-2010 31
Table 20: Critical Care Market, Global, Antithrombin Revenue Segmentation ($'000), 2010-2017 32
Table 21: Critical Care Market, Global, Antithrombin Cost of Therapy ($), 2002-2010 33
Table 22: Critical Care Market, Global, Antithrombin Cost of Therapy ($), 2010-2017 33
Table 23: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern ('000), 2002-2010 34
Table 24: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern ('000), 2010-2017 34
Table 25: Critical Care Market, Global, Fibrinogen Concentrate, Revenue ($m), 2002-2010 41
Table 26: Critical Care Market, Global, Fibrinogen Concentrate, Revenue ($m), 2010-2017 41
Table 27: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($'000), 2002-2010 43
Table 28: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($'000), 2010-2017 43
Table 29: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2002-2010 45
Table 30: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2010-2017 45
Table 31: Critical Care Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern, 2002-2010 47
Table 32: Critical Care Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern, 2010-2017 47
Table 33: Critical Care Market, Global, Albumin Revenue ($m), 2002-2010 52
Table 34: Critical Care Market, Global, Albumin Revenue ($m), 2010-2017 52
Table 35: Critical Care Market, Global, Albumin Revenue Segmentation ($m), 2002-2010 53
Table 36: Critical Care Market, Global, Albumin Revenue Segmentation ($m), 2010-2017 54
Table 37: Critical Care Market, Global, Albumin Cost of Therapy ($), 2002-2010 55
Table 38: Critical Care Market, Global, Albumin Cost of Therapy ($), 2010-2017 55
Table 39: Critical Care Market, Global, Albumin, Number of Patients on Albumin Therapy ('000), 2002-2010 56
Table 40: Critical Care Market, Global, Albumin, Number of Patients on Albumin Therapy ('000), 2010-2017 56
Table 41: Critical Care Market, Global, PCC, Revenue ($m), 2002-2010 62
Table 42: Critical Care Market, Global, PCC, Revenue ($m), 2010-2017 62
Table 43: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2002-2010 64
Table 44: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2010-2017 65
Table 45: Critical Care Market, Global, PCC, Cost of Therapy ($), 2002-2010 66
Table 46: Critical Care Market, Global, PCC, Cost of Therapy ($), 2010-2017 66
Table 47: Critical Care Market, Global, PCC, Number of Patients on PCC, 2002-2010 66
Table 48: Critical Care Market, Global, PCC, Number of Patients on PCC, 2010-2017 67
Table 49: Critical Care Market, Product Pipeline by Indication, 2011 71
List of Figures
1.2 List of Figures
Figure 1: Critical Care Market, Global Revenue ($m), 2002-2017 11
Figure 2: Critical Care Market, Global Revenue Share (%), 2010 12
Figure 3: Critical Care Market, The US, Revenue ($m), 2002-2017 13
Figure 4: Critical Care Market, Global, Revenue ($m), 2002-2017 14
Figure 5: Critical Care Market, Top Five Countries of Europe, Revenue ($m), 2002-2017 15
Figure 6: Critical Care Market, Japan, Revenue ($m), 2002-2017 16
Figure 7: Critical Care Market, Global, Factor XIII Concentrate, Revenue ($'000), 2002-2017 18
Figure 8: Critical Care Market, Global, Factor XIII Concentrate Market Breakup (%), 2010 19
Figure 9: Critical Care Market, Global, Factor XIII Concentrate, Revenue Segmentation ($'000), 2002-2017 21
Figure 10: Critical Care Market, Global, Factor XIII Concentrate, Cost of Therapy ($), 2002-2017 22
Figure 11: Critical Care Market, Global, Factor XIII Concentrate, Treatment Usage Pattern, 2002-2017 24
Figure 12: Critical Care Market, Global, Factor XIII Concentrate Market, Drivers and Restraints, 2010 25
Figure 13: Critical Care Market, Global, Antithrombin, Revenue ($'000), 2002-2017 29
Figure 14: Critical Care Market, Global Antithrombin Market Breakup (%), 2010 30
Figure 15: Critical Care Market, Global, Antithrombin, Revenue Segmentation ($m), 2002-2017 31
Figure 16: Critical Care Market, Global, Antithrombin Cost of Therapy ($), 2002-2017 32
Figure 17: Critical Care Market, Global, Antithrombin, Treatment Usage Pattern ('000), 2002-2017 33
Figure 18: Critical Care Market, Global Antithrombin Market, Drivers and Restraints, 2010 35
Figure 19: Critical Care Market, Global, Fibrinogen Concentrate, Revenue ($m), 2002-2017 41
Figure 20: Critical Care Market, Global, Fibrinogen Concentrate, Revenue Segmentation ($m), 2002-2017 42
Figure 21: Critical Care Market, Global Fibrinogen Concentrate Market Breakup (%), 2010 43
Figure 22: Critical Care Market, Global, Fibrinogen Concentrate, Cost of Therapy ($), 2002-2017 45
Figure 23: Critical Care Market, Global, Fibrinogen Concentrate, Treatment Usage Pattern, 2002-2017 46
Figure 24: Critical Care Market, Global Fibrinogen Concentrate Market, Drivers and Restraints, 2010 48
Figure 25: Critical Care Market, Global, Albumin Revenue ($m), 2002-2017 52
Figure 26: Critical Care Market, Global, Albumin Revenue Segmentation ($m), 2002-2017 53
Figure 27: Critical Care Market, Global, Albumin Cost of Therapy ($), 2002-2017 55
Figure 28: Critical Care Market, Global, Albumin, Number of Patients on Albumin Therapy, 2002-2017 56
Figure 29: Critical Care Market, Global Albumin Market, Drivers and Restraints, 2010 57
Figure 30: Critical Care Market, Global, PCC, Revenue ($m), 2002-2017 62
Figure 31: Critical Care Market, Global, PCC Market Breakup (%), 2010 63
Figure 32: Critical Care Market, Global, PCC, Revenue Segmentation ($m), 2002-2017 64
Figure 33: Critical Care Market, Global, PCC, Cost of Therapy ($), 2002-2017 65
Figure 34: Critical Care Market, Global, PCC, Number of Patients on PCC, 2002-2017 66
Figure 35: Critical Care Market, Global PCC Market, Drivers and Restraints, 2010 67
Figure 36: Critical Care Market, SWOT Analysis of CSL Behring, 2010 74
Figure 37: Critical Care Market, SWOT Analysis of Octapharma, 2010 75
Figure 38: Critical Care Market, SWOT Analysis of Baxter, 2010 76
Figure 39: Critical Care Market, SWOT Analysis of Grifols, 2010 78
Figure 40: Critical Care Market, SWOT Analysis of LFB, 2010 79
Figure 41: GBI Research Market Forecasting Model 85
Companies Mentioned
CSL Limited
Octapharma AG
Baxter International Inc.
Grifols SA (Grifols)
LFB S.A. (LFB)
To order this report:
Therapy Industry: Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles
Check our Industry Analysis and Insights
CONTACT
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article